¶ Moderna COVID-19 vaccine
The Moderna COVID-19 vaccine is a term used to describe multiple COVID-19 vaccine candidates and products developed by Moderna, primarily mRNA-1273. It is also marketed by its brand name, Spikevax.
¶ History
On November 9, 2020, David E. Martin was interviewed on Children's Health Defense's CHD.TV by Robert F. Kennedy Jr. on the subject of the Moderna COVID-19 vaccine.[1]
In early September 2021, Moderna announced that National Resilience would manufacture the synthetic mRNA components of its COVID-19 vaccine for delivery worldwide, including the newer "bivalent" product.[2]
In September 2021, Public Health Ontario adjusted its guidance to suggest youth aged 18-24 receive the Pfizer-BioNTech COVID-19 vaccine instead of the Moderna COVID-19 vaccine product due to elevated risk of myocarditis. However, individuals in that group could still receive the Moderna shot so long as they gave "informed consent."[3]
On February 28, 2022, Arbutus Biopharma and Genevant Sciences filed a lawsuit against Moderna, accusing the company of seven counts of patent infringement related to the Moderna COVID-19 vaccine.[4] The suit alleged that Moderna had licensed Arbutus' lipid nanoparticle (LNP) technology for its products, but not specifically for mRNA-1273. While the companies sought financial compensation, but insisted they did not intend to halt or otherwise impede the distribution of the product. Moderna denied the allegations, claiming it had created its own proprietary lipid nanoparticle delivery technology for use in its mRNA platform.
On July 14, 2022, Health Canada authorized the use of mRNA-1273 for children 6 months to five years old.[5] This marked the first such product authorized for that age group in Canada.
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and Genevant Sciences.[6][7]
Moderna submitted an application to Health Canada on June 29, 2023 for a new formulation of the Moderna COVID-19 vaccine based on the "Omicron XBB.1.5 subvariant" of SARS-CoV-2. It was subsequently authorized by Health Canada on September 12, 2023.[8][9]
On October 15, 2023, an analysis led by the Food and Drug Administration (FDA) was published as a pre-print on medRxiv, in which "a new signal was detected for seizures/convulsions" in children 2-5 years old who received mRNA-1273.[10][11]
In late December 2023, Health Canada officials discussed concerns of frameshifting in the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines. On December 22, 2023, Senior HC Advisor Poovadan Anoop "struck out" mention of the frameshifting issue from a final draft of an internal HC assessment to be sent to Chief Medical Advisor Supriya Sharma.[12]
¶ Safety issues
As early as May 2021, SARS-CoV-2 spike proteins had been identified in blood samples taken from people who have been injected with mRNA-1273. This demonstrated that the antigens enter the bloodstream and circulate around the body for up to 15 days after the first dose.[13]
A study published in September 2022 found that circulating spike protein is associated with a wide range long-term symptoms broadly diagnosed as COVID-19.[14] Such symptoms include fatigue, shortness of breath, chest pain, cognitive disturbances, arthralgia and decline in quality of life[15] - all of which are known adverse events associated with mRNA-1273 and/or COVID-19 vaccines in general.[16][17][18]
¶ External links
David E. Martin on Fauci, Moderna. (2020, November 9). CHD.TV; Children’s Health Defense. https://web.archive.org/web/20231227213517/https://live.childrenshealthdefense.org/chd-tv/shows/truth-with-robert-f-kennedy-jr/david-e-martin-on-fauci-moderna/ ↩︎
Higgins-Dunn, N. (2021, September 8). Moderna taps National Resilience’s new Canadian manufacturing site for COVID-19 vaccine production duties. Fierce Pharma. https://archive.ph/2022.10.29-065703/https://www.fiercepharma.com/pharma/abbvie-expects-skyrizi-and-rinvoq-eclipse-humiras-sales-peak-ceo-gonzalez-says ↩︎
Casaletto, L. (2021, September 30). Ontario recommending Pfizer over Moderna vaccine for young adults. CityNews Toronto. https://web.archive.org/web/20220716051319/https://toronto.citynews.ca/2021/09/29/ontario-moderna-vaccine-side-effect/ ↩︎
Choi, J. (2022, February 28). Biotech firms allege Moderna hijacked technology to develop COVID-19 vaccine. The Hill. http://archive.today/2022.03.02-223228/https://thehill.com/policy/healthcare/596114-biotech-firms-allege-moderna-hijacked-technology-to-develop-covid-19 ↩︎
Health Canada. (2022, July 13). Health Canada authorizes use of Moderna COVID-19 vaccine in children 6 months to 5 years of age. Government of Canada. https://web.archive.org/web/20220716004905/https://www.canada.ca/en/health-canada/news/2022/07/health-canada-authorizes-use-of-moderna-covid-19-vaccine-in-children-6-months-to-5-years-of-age.html ↩︎
Stieber, Z. (2023, March 13). Judge Rejects Request From Moderna, Moving Key COVID-19 Vaccine Case to Discovery. The Epoch Times. http://archive.today/2023.03.13-173504/https://www.theepochtimes.com/judge-rejects-request-from-moderna-moving-key-covid-19-vaccine-case-to-discovery_5119082.html ↩︎
Goldberg, M. (2023). Case 1:22-cv-00252-MSG Document 64. Document Cloud; United States District Court for the District of Delaware. https://web.archive.org/web/20230316161451/https://s3.documentcloud.org/documents/23706145/moderna-covid-19-opinion.pdf ↩︎
Health Canada. (2023, September 12). Health Canada authorizes Moderna COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant. Government of Canada. http://archive.today/2023.09.15-020747/https://www.canada.ca/en/health-canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-the-omicron-xbb15-subvariant.html ↩︎
Health Canada. (2023, September 12). Moderna Spikevax COVID-19 vaccines. Government of Canada. https://web.archive.org/web/20230915020847/https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna.html ↩︎
Mandavilli, A. (2023, October 24). Covid Shots May Slightly Raise Stroke Risk in the Oldest Recipients. New York Times. http://archive.today/2023.10.24-193503/https://www.nytimes.com/2023/10/24/health/covid-flu-vaccine-stroke.html ↩︎
Lloyd, P. C., Hu, M., Shoaibi, A., Feng, Y., Wong, H. L., Smith, E. R., Amend, K. L., Kline, A., Beachler, D. C., Gruber, J. F., Mitra, M., Seeger, J. D., Harris, C., Secora, A., Obidi, J., Wang, J., Song, J., McMahill‐Walraven, C. N., Reich, C., & McEvoy, R. (2023). Safety of Monovalent BNT162b2 (Pfizer–BioNTech), mRNA–1273 (Moderna), and NVX–CoV2373 (Novavax) COVID–19 Vaccines in US Children Aged 6 months to 17 years. medRxiv. https://doi.org/10.1101/2023.10.13.23296903 ↩︎
Chartier, N. (2024, February 23). EXCLUSIVE: Health Canada Official Deleted Scientist’s Note Saying mRNA Shots Have “High Level of Impurity”: Internal Emails. The Epoch Times. http://archive.today/2024.02.23-223357/https://www.theepochtimes.com/world/exclusive-health-canada-official-deleted-scientists-note-saying-mrna-shots-have-high-level-of-impurity-internal-emails-5593451 ↩︎
Ogata, A. F., Cheng, C.-A., Desjardins, M., Senussi, Y., Sherman, A. C., Powell, M., Novack, L., Von, S., Li, X., Baden, L. R., & Walt, D. R. (2021). Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clinical Infectious Diseases, 74(4), 715–718. https://doi.org/10.1093/cid/ciab465 ↩︎
Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X. G., Li, J. Z., Alter, G., & Walt, D. R. (2022). Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clinical Infectious Diseases, 76(3), e487–e490. https://doi.org/10.1093/cid/ciac722 ↩︎
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., Ahluwalia, N., Bikdeli, B., Dietz, D., Der-Nigoghossian, C., Liyanage-Don, N., Rosner, G. F., Bernstein, E. J., Mohan, S., Beckley, A. A., & Seres, D. S. (2021). Post-acute COVID-19 syndrome. Nature Medicine, 27(4), 1–15. https://doi.org/10.1038/s41591-021-01283-z ↩︎
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports. (2021). Public Health and Medical Professionals for Transparency; Pfizer. https://web.archive.org/web/20230714210336/https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf ↩︎
Yoshimura, Y., Sasaki, H., Miyata, N., Miyazaki, K., Koji Okudela, Tateishi, Y., Hayashi, H., Kawana-Tachikawa, A., Iwashita, H., Maeda, K., Ihama, Y., Yasuyoshi Hatayama, Akihide Ryo, & Natsuo Tachikawa. (2022). An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination. International Journal of Infectious Diseases, 121, P98-101. https://doi.org/10.1016/j.ijid.2022.04.057 ↩︎
Finsterer, J. (2022). A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose. Cureus, 14(12). https://doi.org/10.7759/cureus.32433 ↩︎